AU785364B2 - Neurosteroids as markers for Alzheimer's disease - Google Patents

Neurosteroids as markers for Alzheimer's disease Download PDF

Info

Publication number
AU785364B2
AU785364B2 AU31142/01A AU3114201A AU785364B2 AU 785364 B2 AU785364 B2 AU 785364B2 AU 31142/01 A AU31142/01 A AU 31142/01A AU 3114201 A AU3114201 A AU 3114201A AU 785364 B2 AU785364 B2 AU 785364B2
Authority
AU
Australia
Prior art keywords
dhea
cells
brain
levels
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU31142/01A
Other languages
English (en)
Other versions
AU3114201A (en
Inventor
Rachel C. Brown
Caterina Cascio
Vassilios Papadopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University Medical Center filed Critical Georgetown University Medical Center
Publication of AU3114201A publication Critical patent/AU3114201A/en
Application granted granted Critical
Publication of AU785364B2 publication Critical patent/AU785364B2/en
Assigned to GEORGETOWN UNIVERSITY reassignment GEORGETOWN UNIVERSITY Alteration of Name(s) of Applicant(s) under S113 Assignors: GEORGETOWN UNIVERSITY MEDICAL CENTER
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
AU31142/01A 2000-01-28 2001-01-26 Neurosteroids as markers for Alzheimer's disease Ceased AU785364B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17869800P 2000-01-28 2000-01-28
US60178698 2000-01-28
PCT/US2001/002476 WO2001055692A2 (en) 2000-01-28 2001-01-26 Neurosteroids as markers for alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007201915A Division AU2007201915A1 (en) 2000-01-28 2007-04-30 Neurosteroids as markers for Alzheimer's disease

Publications (2)

Publication Number Publication Date
AU3114201A AU3114201A (en) 2001-08-07
AU785364B2 true AU785364B2 (en) 2007-02-01

Family

ID=22653575

Family Applications (2)

Application Number Title Priority Date Filing Date
AU31142/01A Ceased AU785364B2 (en) 2000-01-28 2001-01-26 Neurosteroids as markers for Alzheimer's disease
AU2007201915A Abandoned AU2007201915A1 (en) 2000-01-28 2007-04-30 Neurosteroids as markers for Alzheimer's disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2007201915A Abandoned AU2007201915A1 (en) 2000-01-28 2007-04-30 Neurosteroids as markers for Alzheimer's disease

Country Status (8)

Country Link
EP (1) EP1254251B1 (https=)
JP (1) JP2004507712A (https=)
AT (1) ATE370416T1 (https=)
AU (2) AU785364B2 (https=)
CA (1) CA2398358A1 (https=)
DE (1) DE60129932T2 (https=)
ES (1) ES2290111T3 (https=)
WO (1) WO2001055692A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003100092A2 (en) * 2002-05-28 2003-12-04 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases
FR2847038B1 (fr) * 2002-11-07 2005-01-07 Conservatoire Nat Arts Procede de diagnostic de maladies neurodegeneratives
US7576073B2 (en) 2004-05-28 2009-08-18 UNIVERSITé LAVAL Combined therapy for the treatment of parkinson's disease
CN102998464A (zh) * 2011-09-16 2013-03-27 武汉优尔生科技股份有限公司 脱氢表雄酮酶联免疫吸附测定试剂盒的研制方法
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162198A (en) * 1991-02-08 1992-11-10 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of thrombuxane production and platelet aggregation
US6146836A (en) * 1997-05-19 2000-11-14 Bayer Corporation Immunoassays using anti-allotypic monoclonal antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
P.N.A.S., 1994, 91:3220-23 *
P.N.A.S., 1998, 96(6):2862-67 *

Also Published As

Publication number Publication date
WO2001055692A2 (en) 2001-08-02
AU2007201915A1 (en) 2007-05-24
CA2398358A1 (en) 2001-08-02
EP1254251A4 (en) 2004-07-21
AU3114201A (en) 2001-08-07
DE60129932D1 (de) 2007-09-27
ES2290111T3 (es) 2008-02-16
DE60129932T2 (de) 2008-06-19
ATE370416T1 (de) 2007-09-15
JP2004507712A (ja) 2004-03-11
EP1254251A2 (en) 2002-11-06
EP1254251B1 (en) 2007-08-15
WO2001055692A3 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
Brown et al. Pathways of neurosteroid biosynthesis in cell lines from human brain: regulation of dehydroepiandrosterone formation by oxidative stress and β‐amyloid peptide
Brown et al. Oxidative stress-mediated DHEA formation in Alzheimer’s disease pathology
Lütjohann et al. Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain
Naylor et al. Cerebrospinal fluid dehydroepiandrosterone levels are correlated with brain dehydroepiandrosterone levels, elevated in Alzheimer’s disease, and related to neuropathological disease stage
He et al. Intracellular oxidation of allopregnanolone by human brain type 10 17beta-hydroxysteroid dehydrogenase
Strous et al. Lowered DHEA-S plasma levels in adult individuals with autistic disorder
Gezen-Ak et al. Molecular basis of vitamin D action in neurodegeneration: the story of a team perspective
Verdile et al. Luteinizing hormone levels are positively correlated with plasma amyloid-β protein levels in elderly men
Valenti et al. Dehydroepiandrosterone sulfate and cognitive function in the elderly: The InCHIANTI Study
Caruso et al. Sex‐dimorphic changes in neuroactive steroid levels after chronic experimental autoimmune encephalomyelitis
Dursun et al. Amyloid beta 1–42 alters the expression of miRNAs in cortical neurons
AU2007201915A1 (en) Neurosteroids as markers for Alzheimer's disease
Mizoguchi et al. Specific binding and characteristics of 18β-glycyrrhetinic acid in rat brain
Vaňková et al. Reduced sulfotransferase SULT2A1 activity in patients with Alzheimer's disease.
Ribas et al. Selective screening of Niemann–Pick type C Brazilian patients by cholestane-3β, 5α, 6β-triol and chitotriosidase measurements followed by filipin staining and NPC1/NPC2 gene analysis
US9518994B2 (en) Method for diagnosing and monitoring schizophrenia and tauopathies
Jørgensen Oxidatively generated DNA/RNA damage in psychological stress states
US20030213746A1 (en) Neurosteroids as markers for alzheimer's disease
EP1860442A2 (en) Neurosteroids as markers for Alzheimer's disease
Rammouz et al. Oxidative stress-mediated brain dehydroepiandrosterone (DHEA) formation in Alzheimer’s disease diagnosis
Ernst et al. Androstenedione changes steroidogenic activity of SGBS cells
Mayo et al. Neurosteroids: behavioral studies
Perkins et al. Neurosteroids in the pathophysiology and treatment of mood and anxiety disorders
Taylor et al. The neuroendocrinology of anhedonia
Nenezic et al. The Link Between Serum Levels of Dehydroepiandrosterone and Alzheimer’s Disease: A Pilot Study in the Serbian Population